[go: up one dir, main page]

ATE343396T1 - Immunverstärkende zusammensetzung in fester verabreichungsform mit kollagen oder polydimethylsiloxan als trägersubstanzen - Google Patents

Immunverstärkende zusammensetzung in fester verabreichungsform mit kollagen oder polydimethylsiloxan als trägersubstanzen

Info

Publication number
ATE343396T1
ATE343396T1 AT98919633T AT98919633T ATE343396T1 AT E343396 T1 ATE343396 T1 AT E343396T1 AT 98919633 T AT98919633 T AT 98919633T AT 98919633 T AT98919633 T AT 98919633T AT E343396 T1 ATE343396 T1 AT E343396T1
Authority
AT
Austria
Prior art keywords
immuno
polydimethylsiloxane
collagen
carriers
administration form
Prior art date
Application number
AT98919633T
Other languages
English (en)
Inventor
Keiji Fujioka
Akihiko Sano
Shunji Nagahara
Malcolm Roy Brandon
Andrew Donald Nash
Shari Lofthouse
Original Assignee
Dainippon Sumitomo Pharma Co
Univ Melbourne
Koken Company Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dainippon Sumitomo Pharma Co, Univ Melbourne, Koken Company Ltd filed Critical Dainippon Sumitomo Pharma Co
Application granted granted Critical
Publication of ATE343396T1 publication Critical patent/ATE343396T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0092—Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT98919633T 1997-05-19 1998-05-18 Immunverstärkende zusammensetzung in fester verabreichungsform mit kollagen oder polydimethylsiloxan als trägersubstanzen ATE343396T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP14592097 1997-05-19
JP14246197 1997-05-30
JP31628597 1997-10-30

Publications (1)

Publication Number Publication Date
ATE343396T1 true ATE343396T1 (de) 2006-11-15

Family

ID=27318454

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98919633T ATE343396T1 (de) 1997-05-19 1998-05-18 Immunverstärkende zusammensetzung in fester verabreichungsform mit kollagen oder polydimethylsiloxan als trägersubstanzen

Country Status (12)

Country Link
US (1) US20110217366A1 (de)
EP (1) EP0983088B1 (de)
KR (1) KR100574216B1 (de)
CN (1) CN1150033C (de)
AT (1) ATE343396T1 (de)
AU (1) AU740133B2 (de)
BR (1) BR9809656A (de)
CA (1) CA2290696C (de)
DE (1) DE69836268T2 (de)
NZ (1) NZ500967A (de)
TW (1) TW586934B (de)
WO (1) WO1998052605A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5055455A (en) 1988-09-28 1991-10-08 Brigham And Women's Hospital Capsular polysaccharide adhesin antigen, preparation, purification and use
US7252828B2 (en) 1998-07-15 2007-08-07 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for staphylococcal infections
AUPP646798A0 (en) * 1998-10-12 1998-11-05 Csl Limited Fibrin glue as a biological adjuvant
WO2000050584A2 (en) * 1999-02-24 2000-08-31 University Of Iowa Research Foundation Methods and compositions for enhancing in vivo gene delivery/expression
AU2001263760A1 (en) 2000-04-11 2001-11-07 Polyzenix Gmbh Poly-tri-fluoro-ethoxypolyphosphazene coverings and films
JP2002003396A (ja) * 2000-06-20 2002-01-09 Adaputogen Seiyaku Kk 免疫増強剤及びその製造方法
WO2003015719A1 (de) 2001-08-17 2003-02-27 Polyzenix Gmbh Vorrichtung auf basis von nitinol mit polyphosphazenüberzug
US9080146B2 (en) 2001-01-11 2015-07-14 Celonova Biosciences, Inc. Substrates containing polyphosphazene as matrices and substrates containing polyphosphazene with a micro-structured surface
DE10100961B4 (de) 2001-01-11 2005-08-04 Polyzenix Gmbh Körperverträglicher Werkstoff und mit diesem Werkstoff beschichtetes Substrat für die Züchtung von Zellen und künstlichen aus Zellen aufgebauten oder gewachsenen organischen Implantaten
US20050129776A1 (en) 2002-05-03 2005-06-16 Inserm Microparticles supporting cells and active substances
WO2004043407A2 (en) 2002-11-12 2004-05-27 The Brigham And Women's Hospital, Inc. Methods and products for treating staphylococcal infections
DK1565478T3 (da) 2002-11-12 2017-11-13 Brigham & Womens Hospital Inc Polysaccharidvaccine mod stafylokokinfektioner
AU2003901008A0 (en) * 2003-03-04 2003-03-20 Anadis Ltd Composition for the treatment and prevention of bacterial infections
SI1745075T1 (sl) 2004-04-21 2013-07-31 The Brigham And Women's Hospital, Inc. Poli-N-acetilglukozamin (PNAG/dPNAG) vezavni peptidi in postopki za njihovo uporabo
CA2583061C (en) 2004-10-06 2015-02-17 Kwang Guan Tay Antibody production method
US20210299056A9 (en) 2004-10-25 2021-09-30 Varian Medical Systems, Inc. Color-Coded Polymeric Particles of Predetermined Size for Therapeutic and/or Diagnostic Applications and Related Methods
US9107850B2 (en) 2004-10-25 2015-08-18 Celonova Biosciences, Inc. Color-coded and sized loadable polymeric particles for therapeutic and/or diagnostic applications and methods of preparing and using the same
US9114162B2 (en) 2004-10-25 2015-08-25 Celonova Biosciences, Inc. Loadable polymeric particles for enhanced imaging in clinical applications and methods of preparing and using the same
BRPI0717738A2 (pt) 2006-10-10 2018-09-11 Celonova Biosciences Inc válvula cardíaca bioprotética, método de fabricação da mesma, método de aperfeiçoamento das qualidades anti-trombogênicas de biocompatibilidade ou hemocaptabilidade de uma válvula cardíaca bioprotética
EP2121048B9 (de) 2007-02-19 2016-02-24 Marine Polymer Technologies, Inc. Blutstillende zusammensetzungen und therapeutische verfahren dafür
AU2009274630B2 (en) 2008-07-21 2014-05-08 The Brigham And Women's Hospital, Inc. Methods and compositions relating to synthetic beta-1,6 glucosamine oligosaccharides
CN102448488B (zh) * 2009-06-04 2014-10-15 独立行政法人产业技术综合研究所 支原体感染症用疫苗
CN101690810B (zh) * 2009-10-21 2011-08-17 辽宁益康生物股份有限公司 一种鸡新城疫、传染性支气管炎、减蛋综合征、禽流感四联灭活疫苗佐剂及其制备方法
KR101518866B1 (ko) * 2013-08-08 2015-05-21 연세대학교 원주산학협력단 락토바실러스 플랜타룸 및 이의 용도
KR101647299B1 (ko) * 2015-04-10 2016-08-10 성균관대학교산학협력단 암 백신 조성물 및 이의 제조 방법
CN117886953B (zh) * 2024-01-17 2024-08-09 华中农业大学 重组AaLS-IDR-1047免疫增强肽、制备方法及应用

Family Cites Families (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3469003A (en) * 1966-04-01 1969-09-23 Haver Lockhart Lab Inc Injectable reconstituted collagen fluid adjuvant for vaccines and other drugs
JPS5540568B2 (de) * 1972-10-05 1980-10-18
US3958025A (en) * 1972-10-06 1976-05-18 Livingston Virginia W C Abscisic acid tablets and process
US4488911A (en) * 1975-10-22 1984-12-18 Luck Edward E Non-antigenic collagen and articles of manufacture
US4277249A (en) * 1979-10-15 1981-07-07 Nichols Institute Mammalian Somatomedin measurement
US4423895A (en) * 1981-04-22 1984-01-03 Mosley Jr Thomas C Dead-bolt-type locking means, and an assembly thereof
FR2516927B1 (fr) * 1981-11-26 1986-05-23 Merieux Fond Procede de preparation industrielle de materiaux collageniques a partir de tissus placentaires humains, materiaux collageniques humains obtenus, leur application comme biomateriaux
US5833975A (en) * 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
JPS59164723A (ja) * 1983-03-10 1984-09-17 Koken:Kk 再生コラーゲンフイブリルを含有する基質及びその製造方法
DE3331627A1 (de) * 1983-09-01 1985-03-21 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen Verfahren zur immunologischen bestimmung fuer proteine in koerperfluessigkeiten, unter verwendung monovalenter antikoerperfragmente
US4855134A (en) * 1983-10-14 1989-08-08 Sumitomo Pharmaceuticals Company, Limited Sustained-release preparation
US5385738A (en) * 1983-10-14 1995-01-31 Sumitomo Pharmaceuticals Company, Ltd. Sustained-release injection
US4774091A (en) * 1983-10-14 1988-09-27 Sumitomo Pharmaceuticals Company, Ltd. Long-term sustained-release preparation
CA1341617C (en) * 1984-06-08 2011-06-28 Henry George Burger Inhibin isolated from ovarian follicular fluid
US5288497A (en) * 1985-05-01 1994-02-22 The University Of Utah Compositions of oral dissolvable medicaments
NZ217844A (en) * 1985-10-11 1989-10-27 Sumitomo Pharma A sustained release pharmaceutical composition containing silicone elastomer and an albumin
ATE87469T1 (de) * 1985-12-27 1993-04-15 Sumitomo Pharma Verfahren zur herstellung einer formulierung mit verzoegerter freisetzung.
DE3684446D1 (de) * 1985-12-28 1992-04-23 Sumitomo Pharma Arzneimittel mit verzoegerter stossweiser freisetzung.
US4959217A (en) * 1986-05-22 1990-09-25 Syntex (U.S.A.) Inc. Delayed/sustained release of macromolecules
DE3789320T2 (de) * 1986-07-30 1994-06-09 Sumitomo Pharma Verabreichungsinstrument zum Einführen von festen Medikamenten.
EP0290269A3 (de) * 1987-05-06 1989-08-09 Cyberfluor Inc. Immunoassayverfahren und Reagenzien und Herstellungsverfahren der letzteren
JPH0720483B2 (ja) * 1987-05-29 1995-03-08 住友製薬株式会社 高粘度糊状組成物成形体の乾燥法
US4894231A (en) * 1987-07-28 1990-01-16 Biomeasure, Inc. Therapeutic agent delivery system
ATE90570T1 (de) * 1988-01-29 1993-07-15 Sumitomo Pharma Verbesserte formulierungen mit kontrollierter abgabe.
EP0368992B1 (de) * 1988-05-31 1995-02-15 Biotechnology Australia Pty. Ltd. Wirkung von hormonen
US5135915A (en) * 1988-10-14 1992-08-04 Genentech, Inc. Method for the treatment of grafts prior to transplantation using TGF-.beta.
US5306500A (en) * 1988-11-21 1994-04-26 Collagen Corporation Method of augmenting tissue with collagen-polymer conjugates
US5244672A (en) * 1988-12-02 1993-09-14 Coletica Composition containing liposomes stabilized by a stabilizing support based on atelocollagen and glycosaminoglycans
US5395620A (en) * 1989-01-31 1995-03-07 Coletica Biodegradable microcapsules having walls composed of crosslinked atelocollagen and polyholoside
AU624962B2 (en) * 1989-06-20 1992-06-25 Merrell Dow Pharmaceuticals Inc. Ghilanten: antimetastatic principle from the south american leech, haementeria ghilanii
KR0177179B1 (ko) * 1989-07-14 1999-03-20 알퐁스 아아르 노에 인터루킨을 함유하는 안정한 백신 조성물
US6126945A (en) * 1989-10-03 2000-10-03 Pharmacia Ab Tumor killing effects of enterotoxins, superantigens, and related compounds
JP2546447Y2 (ja) * 1989-10-23 1997-09-03 富士機工株式会社 自在継手
FR2659554B1 (fr) * 1990-03-16 1994-09-30 Oreal Composition pour le traitement cosmetique et/ou pharmaceutique des couches superieures de l'epiderme par application topique sur la peau et procede de preparation correspondant.
IT1248934B (it) * 1990-06-01 1995-02-11 Fidia Spa Membrane forate biocompatibili,processi per la loro preparazione,loro impiego come supporto per la crescita in vitro di cellule epiteliali, pelli artificiali cosi' ottenute e loro impiego nei trapianti di pelle
US5612198A (en) * 1990-09-04 1997-03-18 The Salk Institute Production of insulin-like growth factor-1 in methylotrophic yeast cells
US5216004A (en) * 1990-09-13 1993-06-01 Children's Hospital Medical Center Of North California Method for preventing malaria
US5187151A (en) * 1991-02-12 1993-02-16 Genentech, Inc. Use of binding protein with igf-i as an anabolic growth promoting agent
WO1992017209A1 (en) * 1991-04-08 1992-10-15 Sumitomo Pharmaceuticals Company, Limited Porous solid preparation containing physiologically active protein substance
US5314874A (en) * 1991-04-19 1994-05-24 Koken Co., Ltd. Intracorporeally injectable composition for implanting highly concentrated cross-linked atelocollagen
US5563124A (en) * 1991-04-22 1996-10-08 Intermedics Orthopedics/ Denver, Inc. Osteogenic product and process
AU654574B2 (en) * 1991-06-14 1994-11-10 Amgen, Inc. Collagen film drug delivery for proteins
US5648208A (en) * 1991-08-01 1997-07-15 Coletica Use of a collagen as solid binding substrate for a ligand capable of reacting specifically with an element to be detected in a biological medium, reactant and implementation
US5679348A (en) * 1992-02-03 1997-10-21 Cedars-Sinai Medical Center Immunotherapy for recurrent HSV infections
US5428011A (en) * 1992-06-16 1995-06-27 Procyon Biopharma, Inc. Pharmaceutical preparations for inhibiting tumours associated with prostate adenocarcinoma
WO1994000484A1 (en) * 1992-06-22 1994-01-06 Young Henry E Scar inhibitory factor and use thereof
US5338836A (en) * 1992-07-29 1994-08-16 American Cyanamid Company Biologically active porcine somatotropin polypeptides and methods of using the same
FR2703927B1 (fr) * 1993-04-13 1995-07-13 Coletica Utilisation d'une réaction de transacylation entre un polysaccharide estérifié et une polyamine pour former en milieu aqueux une membrane au moins en surface de particules gélifiées.
US5824651A (en) * 1993-05-10 1998-10-20 Universite De Montreal Process for modification of implant surface with bioactive conjugates for improved integration
US6030615A (en) * 1993-05-17 2000-02-29 The Picower Institute For Medical Research Combination method for treating diseases caused by cytokine-mediated toxicity
GB9310781D0 (en) * 1993-05-25 1993-07-14 Davis Stanley S Preparation of microparticles
JPH0767895A (ja) * 1993-06-25 1995-03-14 Sumitomo Electric Ind Ltd 抗菌性人工血管及び抗菌性手術用縫合糸
JPH08512056A (ja) * 1993-06-30 1996-12-17 ジェネンテク・インコーポレイテッド リポソームの製造法
US5469559A (en) * 1993-07-06 1995-11-21 Dell Usa, L.P. Method and apparatus for refreshing a selected portion of a dynamic random access memory
AU1218295A (en) * 1993-12-09 1995-06-27 Heinrich Exner Adjuvant for antigens, process for producing the same and its use
JP3720386B2 (ja) * 1993-12-27 2005-11-24 住友製薬株式会社 薬物放出制御製剤
CA2140053C (en) * 1994-02-09 2000-04-04 Joel S. Rosenblatt Collagen-based injectable drug delivery system and its use
US5942496A (en) * 1994-02-18 1999-08-24 The Regent Of The University Of Michigan Methods and compositions for multiple gene transfer into bone cells
US20030171283A1 (en) * 1994-02-28 2003-09-11 Satterlee Daniel G. Inhibin compositions and methods of enhancing production performance
US5961979A (en) * 1994-03-16 1999-10-05 Mount Sinai School Of Medicine Of The City University Of New York Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
US5466233A (en) * 1994-04-25 1995-11-14 Escalon Ophthalmics, Inc. Tack for intraocular drug delivery and method for inserting and removing same
DE4414755C2 (de) * 1994-04-27 2000-11-16 Lohmann Therapie Syst Lts Kollagenzubereitung zur gesteuerten Abgabe von Wirkstoffen, Verfahren und Verwendung
AUPM543894A0 (en) * 1994-05-04 1994-05-26 Commonwealth Scientific And Industrial Research Organisation An adjuvant
US5571531A (en) * 1994-05-18 1996-11-05 Mcmaster University Microparticle delivery system with a functionalized silicone bonded to the matrix
US5705399A (en) * 1994-05-20 1998-01-06 The Cooper Union For Advancement Of Science And Art Sensor and method for detecting predetermined chemical species in solution
US5681568A (en) * 1994-08-19 1997-10-28 Cambridge Neuroscience, Inc. Device for delivery of substances and methods of use thereof
US5679654A (en) * 1994-09-02 1997-10-21 Brigham & Women's Hospital, Inc. Capsular polysaccharide immunomodulator
US5837533A (en) * 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
DK0784483T3 (da) * 1994-10-03 2001-03-26 Us Gov Health & Human Serv Præparat indeholdende et rekombinant virus, der udtrykker et antigen, og et rekombinant virus, der udtrykker et immunstimul
US5916790A (en) * 1995-03-03 1999-06-29 Metabolex, Inc. Encapsulation compositions, and methods
KR100201352B1 (ko) * 1995-03-16 1999-06-15 성재갑 단일주사 백신 제형
US5750146A (en) * 1995-04-28 1998-05-12 Matrix Pharmaceutical, Inc. Translucent collagen formulations with a cytotoxic drug
US5677284A (en) * 1995-06-06 1997-10-14 Regen Biologics, Inc. Charged collagen particle-based delivery matrix
AU716005B2 (en) * 1995-06-07 2000-02-17 Cook Medical Technologies Llc Implantable medical device
US6998268B2 (en) * 1995-07-03 2006-02-14 Dainippon Sumitomo Pharma Co. Ltd. Gene preparations
US5827937A (en) * 1995-07-17 1998-10-27 Q Med Ab Polysaccharide gel composition
US6254872B1 (en) * 1995-08-25 2001-07-03 University Of Florida Multi-subtype FIV vaccines
US5665391A (en) * 1995-10-12 1997-09-09 Spectral Diagnostics Inc. Cultured, full-thickness integument substitutes based on three-dimensional matrix membranes
US5965125A (en) * 1995-10-25 1999-10-12 Transkaryotic Therapies, Inc. Hybrid matrix implants and explants
US5888497A (en) * 1996-04-03 1999-03-30 The Rogosin Institute Agarose coated agarose beads containing cancer cells that produce material which suppresses cancer cell proliferation
CA2217134A1 (en) * 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Sustained release formulation
JPH10139670A (ja) * 1996-11-11 1998-05-26 Terukuni Yakida インターロイキン１２誘導物質及び医薬組成物
US6083522A (en) * 1997-01-09 2000-07-04 Neucoll, Inc. Devices for tissue repair and methods for preparation and use thereof
US6143276A (en) * 1997-03-21 2000-11-07 Imarx Pharmaceutical Corp. Methods for delivering bioactive agents to regions of elevated temperatures
CA2304665A1 (en) * 1997-09-30 1999-04-08 Cel-Sci Corporation Immunogenic conjugated polypeptide for treatment of herpes simplex virus
US5935577A (en) * 1998-01-23 1999-08-10 Autoimmune Inc. Treatment of autoimmune disease using tolerization in combination with methotrexate
CA2329129C (en) * 1998-05-22 2009-02-24 Sumitomo Pharmaceuticals Company, Limited Stable gene formulations comprising saccharides
AU754996B2 (en) * 1998-09-10 2002-11-28 Sumitomo Dainippon Pharma Co., Ltd. Long time drug-sustained release preparation
US6692752B1 (en) * 1999-09-08 2004-02-17 Smithkline Beecham Biologicals S.A. Methods of treating human females susceptible to HSV infection
US6544785B1 (en) * 1998-09-14 2003-04-08 Mount Sinai School Of Medicine Of New York University Helper-free rescue of recombinant negative strand RNA viruses
US6689153B1 (en) * 1999-04-16 2004-02-10 Orthopaedic Biosystems Ltd, Inc. Methods and apparatus for a coated anchoring device and/or suture
US6486134B2 (en) * 1999-09-17 2002-11-26 Leadergene Limited Gene treatment to enhance feed efficiency and growth rate of livestock
US6551598B2 (en) * 2000-01-21 2003-04-22 Merial Vaccination against canine herpesvirosis and vaccines therefor
PT1295611E (pt) * 2000-06-20 2010-09-14 Dainippon Sumitomo Pharma Co Preparações para transferência de oligonucleótidos
DE60135352D1 (de) * 2000-08-30 2008-09-25 Univ Johns Hopkins Vorrichtung zur intraokularen wirkstoffverabreichung
AU784975B2 (en) * 2000-10-11 2006-08-10 Sumitomo Chemical Company, Limited DNA-binding protein YB-1-containing collagen accumulation inhibitors
US20050129728A1 (en) * 2001-09-11 2005-06-16 Martinod Serge R. Sustained release pharmaceutical composition
WO2003022242A1 (en) * 2001-09-11 2003-03-20 Smart Drug Systems Inc Preparation of sustained release pharmaceutical composition
AUPR951501A0 (en) * 2001-12-14 2002-01-24 Smart Drug Systems Inc Modified sustained release pharmaceutical system
CN1638747A (zh) * 2002-01-24 2005-07-13 斯玛特药物系统公司 持续释放药物组合物
US20060258602A1 (en) * 2002-09-20 2006-11-16 Yukio Ando Site-specific gene conversion promoter and gene therapeutic

Also Published As

Publication number Publication date
EP0983088B1 (de) 2006-10-25
CA2290696C (en) 2010-09-14
AU7238598A (en) 1998-12-11
DE69836268D1 (de) 2006-12-07
NZ500967A (en) 2001-09-28
EP0983088A1 (de) 2000-03-08
BR9809656A (pt) 2000-07-11
CN1263470A (zh) 2000-08-16
CN1150033C (zh) 2004-05-19
KR20010012769A (ko) 2001-02-26
US20110217366A1 (en) 2011-09-08
WO1998052605A1 (en) 1998-11-26
TW586934B (en) 2004-05-11
DE69836268T2 (de) 2007-05-31
KR100574216B1 (ko) 2006-04-27
CA2290696A1 (en) 1998-11-26
AU740133B2 (en) 2001-11-01

Similar Documents

Publication Publication Date Title
ATE343396T1 (de) Immunverstärkende zusammensetzung in fester verabreichungsform mit kollagen oder polydimethylsiloxan als trägersubstanzen
ATE224184T1 (de) Verfahren zur mikroverkapselung von antigenen und verwendung der zusammensetzungen als impfstoffe
ATE200679T1 (de) Neues verfahren zur herstellung von anti-humanen antigenrezeptoren und deren verwendungen
ATE160787T1 (de) Verfahren zur herstellung von hefe-glucanen
ATE47155T1 (de) Monoklonaler antikoerper.
DE69519670D1 (de) Mikropartikel mit abgabesystem
BR9708387A (pt) Processo para vacinação de um mamìfero a um antìgeno selecionado, células patogênica e hospedeira, composição de vacina, ácido nucleico, e, opsonina engenheirada.
NO933126D0 (no) Loeselige ligander for cd40
DK88385A (da) Biologisk nedbrydeligt polypeptid samt anvendelse deraf til gradvis frigivelse af laegemidler
ES2089199T3 (es) Composicion curable.
DK0570489T3 (da) Leverstadium-specifikke peptidsekvenser af P.falciparum, der bærer epitoper, som er i stand til at stimulere T-lymfocytter
ATE322285T1 (de) Verfahren zur induktion der zellulären immunantwort und parenterale impfstoff- zusammensetzungen dazu
DK0480949T4 (da) Fremstilling af virusvaccine
IL139601A0 (en) Compositions and methods of modulating an immune response to an antigen
DE69833455D1 (de) Methoden und zusammensetzungen zur erhöhung der immunantwort und zur herstellung von in-vitro monoklonalen antikörpern (mabs)
ATE96675T1 (de) Spezifische sekretions-exkretions-antigene von toxoplasma gondii, deren expressionsprodukte, verfahren zu deren herstellung und deren diagnostische und prophylaktische anwendungen.
DK0675709T3 (da) Lyofiliseret emulsion indeholdende aktivt stof
ATE87215T1 (de) Verfahren zum erhalten von immunregulierenden faktoren mittels saeugetierimmunisierung.
DE69928523D1 (de) Verotoxin b untereinheit zur immunisierunug
ATE109004T1 (de) Toleranzinduktion gegenüber einem fremdantigen.
SE9501512D0 (sv) Synthetic peptide-defined eptopes useful for vaccination against papillomavirus
DK1226176T3 (da) Produktion af brystsekret-antistoffer i landbrugsdyr
ATE318300T1 (de) Isolierte stämme von staphylococcus aureus und daraus hergestellte impfstoffe
DE59814423D1 (de) Verfahren zur herstellung von humaneigenblutzytokinen
DE69617255D1 (de) Durch hla-b44 moleküle präsentierte tumor-abstossungsantigene und ihre verwendung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties